[Ip-health] HRC34: Intervention of the United States of America - Panel discussion on access to medicines
mkamalyanni at Oxfam.org.uk
Fri Mar 10 05:28:47 PST 2017
Why does the US always speaks about access to medicine as a problem for
the rest of the world and not their own country? Presumably they don't
have these problems of "Inappropriate tax and tariff policies,
insufficient health systems, inadequate access to financing, or lack of
essential procurement systems " or they would have implemented their own
advice " There is nothing preventing Member States from taking immediate
domestic action to reduce these barriers."
Why do they behave as if everything is OK in the US? Do they read/watch
their local news?
Best wishes for a sane, just and peaceful 2017 مع أطيب التمنيات لعالم
أكثر عقلا’ وعدلآ وسلامأ
Mohga dictating to the computer so please ignore silly mistakes
Senior health & HIV policy advisor, Oxfam GB
Editor of www.globalhealthcheck.org
John Smith Drive, Oxford, OX4 2JY, UK (GMT, CET-1, EDT+5, EST+6)
UK Mobile + 44 (0)777 62 55 884
Follow me @MohgaKamalYanni
From: Thiru Balasubramaniam <thiru at keionline.org>
To: "ip-health at lists.keionline.org" <Ip-health at lists.keionline.org>
Date: 09/03/2017 10:26
Subject: [Ip-health] HRC34: Intervention of the United States of
America - Panel discussion on access to medicines
Sent by: "Ip-health" <ip-health-bounces at lists.keionline.org>
*Intervention of the United States of America**Human Rights Council 34*
*Panel discussion on access to medicines**As Delivered by Robert Waller*
*Geneva, March 8, 2017*
Thank you, Chair.
The United States believes achieving greater access to medicines,
particularly to essential medicines, is a complex challenge. We are
committed to identifying practical ways to increase access to safe,
effective, and affordable medicines around the world, and to support
policies that drive development of new medicines, including promoting
robust intellectual property rights protection and enforcement systems
that provide a predictable environment in which to invest the billions of
dollars necessary to bring life-saving drugs to market.
Regrettably, today’s panel has failed to promote these goals as it
focuses solely and inappropriately on advancing the recommendations of the
report of the United Nations Secretary-General’s High-Level Panel on
Access to Medicines.
The mandate of today’s panel was to “exchange views on good practices and
key challenges relevant to access to medicines…taking into account all
relevant reports.” Unfortunately, the concept note for the panel and its
composition suggest a focus on the HLP report that is inconsistent with
what was agreed to in June last year.
As the United States and others have repeatedly made clear, including at
the meeting of the World Health Organization’s Executive Board, the
High-Level Panel operated under a flawed premise. The HLP report
inappropriately assumes an incoherence between access to medicines,
intellectual property, and trade, and fails to consider critical barriers.
The Panel could not reach consensus on its key recommendations, with two
of the Panelists – the two who had the most extensive experience in
research and development – warning that the Report’s recommendations could
result in serious negative unintended consequences for R&D. Consequently,
today’s panel should not be used as a basis for the Human Rights Council
to further consider the HLP report or for other future work.
This panel’s narrow focus on the HLP deprives states of the opportunity to
consider the reasons why essential medicines that are off-patent are not
reaching patients in some countries. Inappropriate tax and tariff
policies, insufficient health systems, inadequate access to financing, or
lack of essential procurement systems can all serve as internal barriers.
There is nothing preventing Member States from taking immediate domestic
action to reduce these barriers.
In closing, we request that the High Commissioner’s summary report on
today’s panel discussion reflect the concerns we have expressed, including
the concern that the panel’s narrow focus on the HLP is inconsistent with
the mandate in HRC resolution 32/15. We look forward to continue working
with our partners to address this and other critical issues facing our
Ip-health mailing list
Ip-health at lists.keionline.org
Oxfam works with others to overcome poverty and suffering.
Oxfam GB is a member of Oxfam International and a company limited by guarantee registered in England No. 612172.
Registered office: Oxfam House, John Smith Drive, Cowley, Oxford, OX4 2JY.
A registered charity in England and Wales (no 202918) and Scotland (SC 039042)
More information about the Ip-health